Capital – Talk Bio

Bluebird Private Equity Buyout Boosts Upfront Cash for Shareholders

3 weeks ago talkbio0Tagged Capital, Carlyle, contingent value right, CVR, DKK1 gene, Family Turdidae (organism), Merger, Private Equity, shareholders, upfront cash

Bluebird; private equity buyout; shareholders; upfront cash; Carlyle; SK Capital; contingent value right; CVR; buyout terms; merger

Azafaros Raises €132M in Series B to Fund Phase 3 Trials for Brain-Penetrant Drug

4 weeks ago talkbio0Tagged Azafaros, Brain-Penetrant Drug, Capital, Clinical Trials, Forbion, Growth, Jeito, Lysosomal Storage Diseases, neuro-metabolic diseases, Neurodegenerative Disorders, nizubaglustat, Phase 3, Series B funding

Azafaros; Series B funding; nizubaglustat; brain-penetrant drug; lysosomal storage disorders; rare neuro-metabolic diseases; phase 3 clinical trials; Jeito Capital; Forbion Growth; neurodegenerative diseases

Biohaven, after setbacks, sees shares jump with Oberland Capital funding agreement worth up to $600M

1 month ago talkbio0Tagged Approved, Ataxia, Spinocerebellar, Capital, Investments, non-dilutive, Note (document), secured, United States Food and Drug Administration

Biohaven, Oberland Capital, $600 million investment, troriluzole, spinocerebellar ataxia (SCA), non-dilutive funding, FDA approval, senior secured notes

Ayrmid misses deadline for detailed offer to top private equity bid for bluebird

2 months ago talkbio0Tagged Ayrmid, Capital, deadline, Failed, Family Turdidae (organism), gene therapy, Private Equity, proposal - intent, United States Food and Drug Administration

Ayrmid, Family Turdidae (organism), gene therapy, Failed, Capital, proposal – intent, United States Food and Drug Administration, private equity, deadline

Bluebird bio receives rival M&A bid worth 50% higher than Carlyle-SK offer

2 months ago talkbio0Tagged Ayrmid, Bluebird Bio, Capital, Carlyle, Family Turdidae (organism), gene therapy, High, Twice a day

Ayrmid, Family Turdidae (organism), Twice a day, gene therapy, Carlyle, High, Bluebird Bio, Capital

Sofinnova Partners Secures €1.2 Billion for Life Sciences Innovation

3 months ago talkbio0Tagged Capital, digital medicine, Health care facility, Industry, medtech, sustainability, venture

Venture capital, biotech, medtech, digital medicine, industrial biotech, healthcare, sustainability

Bluebird Bio’s Fall from Grace: Gene Therapy Pioneer Sells for $29M After $10B Valuation

3 months ago talkbio0Tagged Acquisition, Capital, Carlyle, DKK1 gene, Family Turdidae (organism), Financial Stress, gene therapy, Industry, Private Equity

Bluebird Bio, gene therapy, private equity, Carlyle, SK Capital, financial challenges, acquisition, biotech industry

New year starts with a bang as trio of venture financings brings in $382M

4 months ago talkbio0Tagged biotech, Capital, Investments, Life, Megarounds, Private financing, Tenvie, venture

Venture capital, Biotech funding, Megarounds, Tenvie Therapeutics, Private financing, Life sciences investments

Ouro Medicines Launches with $120M Funding to Develop Immune Reset Therapeutics for Chronic Immune-Mediated Diseases

5 months ago talkbio0Tagged Capital, Chronic Immune-Mediated Diseases, engagers, immune reset, innovations, Monograph, NEA, Norwest, Ouro Medicines, Partner in relationship, SmithKline Beecham, T-Lymphocyte, TPG, venture

Ouro Medicines, Immune Reset Therapeutics, Chronic Immune-Mediated Diseases, T Cell Engagers, B Cell Mediated Diseases, GSK, Monograph Capital, TPG Life Sciences Innovations, NEA, Norwest Venture Partners

Orbis Kicks Off 2025 with €90M Series A Funding in Fierce Biotech Fundraising Tracker

5 months ago talkbio0Tagged biotech, Biotech Fundraising Tracker, Biotech Investments, Capital, Fierce, Funding, funding rounds, Orbis, Series, venture

Fierce Biotech Fundraising Tracker 2025, Orbis Series A Funding, Biotech Venture Capital, 2025 Biotech Investments, Series A Funding Rounds